drugset / Trial / NCT00319930

Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

NCT00319930

Phase 1 Terminated 10 enrolled Biogen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.

Timeline

Start
2005-05
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject tanespimycin Unknown